Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975240 | 0.92 | EGFR (0.64) | EGFRERBB2GAKERBB4 | |
| SCHEMBL9975239 | 0.91 | ERBB2 (0.55) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6978602 | 0.87 | EGFR (0.58) | EGFRERBB2GAKERBB4 | |
| SCHEMBL9975297 | 0.85 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL15304789 | 0.84 | ERBB2 (0.65) | EGFRERBB2GAKERBB4 | |
| SCHEMBL2478977 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL29651885 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL2478975 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6955065 | 0.83 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6980092 | 0.83 | EGFR (0.67) | EGFRERBB2GAKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885GAK 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.